Lapatinib Teva

Lapatinib, the active ingredient in Lapatinib Teva, is a tyrosine kinase inhibitor presented as a tablet for oral use. It targets HER2-positive metastatic breast cancer and HER2-positive gastric cancer in adult patients.

GNH USA supplies Lapatinib Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

Lapatinib is indicated for cancers driven by HER2 signaling and is used as part of combination regimens. - HER2‑positive metastatic breast cancer: used with chemotherapy to delay disease progression. - HER2‑positive gastric cancer: combined with chemotherapy to improve response rates.

Lapatinib may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Diarrhea - Rash or acne‑like skin eruption - Nausea and vomiting - Fatigue - Hand‑foot syndrome - Headache

Serious or Rare Side Effects: - Hepatotoxicity (elevated liver enzymes, hepatitis) - QT interval prolongation leading to cardiac arrhythmia - Severe skin reactions such as Stevens‑Johnson syndrome - Interstitial lung disease or pneumonitis - Severe diarrhea leading to dehydration - Cardiac dysfunction or heart failure

Before initiating therapy, clinicians should assess baseline health status and monitor patients regularly. - Cardiac monitoring: evaluate baseline ejection fraction and repeat as clinically indicated. - Liver function: obtain baseline hepatic enzymes and monitor periodically. - Electrolyte balance: check potassium and magnesium levels, especially if diarrhea occurs. - Drug interactions: avoid concomitant use of strong CYP3A4 inhibitors. - Pregnancy and lactation: use only if potential benefit justifies potential risk; discuss with patient. - Store at ambient temperature: keep in original container, protect from moisture and direct sunlight.

Lapatinib interacts with several drug classes that may alter its exposure or increase toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole) – may raise plasma levels. - Concurrent QT‑prolonging agents – increase risk of cardiac arrhythmia. - Paclitaxel or other taxanes – may amplify hematologic toxicity.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine) – may reduce efficacy. - Antacids containing aluminum or magnesium – may affect absorption; separate dosing by at least 2 hours. - Warfarin – monitor INR for potential changes. - Digoxin – observe serum levels for possible alteration.